|
1) 澤田賢一, 浦部晶夫, 中尾眞二, 他. 赤芽球癆診療の参照ガイド(厚生労働科学研究費補助金, 難治性疾患克服事業, 特発性造血障害に関する調査研究班, 主任研究者 小峰光博). 臨床血液. 2006; 47: 316-30
|
|
|
|
2) Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008; 142: 505-14
|
|
|
|
|
3) Sawada K, Hirokawa M, Fujishima N, et al. For the PRCA Collaborative Study Group. Long-term relapse-free survival and overall survival of patients with acquired primary idiopathic PRCA receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007; 92: 1021-8
|
|
|
|
|
|
4) Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996; 87: 3000-6
|
|
|
|
|
|
5) Mamiya S, Itoh T, Miura AB. Acquired pure red cell aplasia in Japan. Eur J Haematol. 1997; 59: 199-205
|
|
|
|
|
|
6) Chan WC, Catovsky D, Foucar K, et al. T-cell large granular lymphocyte leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. p. 197-8
|
|
|
|
|
|
7) Zeok J, Todd EP, Dillon M, et al. The role of thymectomy in red cell aplasia. Ann Thorac Surg. 1979; 28: 257-60
|
|
|
|
|
|
8) Masaoka A, Hashimoto T, Shibata K, et al. Thymomas associated with pure red cell aplasia. Histologic and follow-up studies. Cancer. 1989; 64: 1872
|
|
|
|
|
|
9) Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Brit J Haematol. 2006; 135: 405
|
|
|
|
|
|
10) Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: A Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008; 93: 27-33
|
|
|
|
|
|
11) Fujishima M, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008; 93: 1555-9
|
|
|
|
|
|
12) Go RS, Li CY, Tefferi A, et al. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001; 98: 483-5
|
|
|
|
|
|
13) Dssypris EN. In: Pure red cell aplasia. Baltimore MD: Johns Hopkins Univ Press; 1988
|
|
|
|
|
|
14) Dessypris EN, Lipton JM. Red cell aplasia. In: Greer JP, Foerster J, Lukens JN, et al editors. Wintrobe's Clinical Hematology, 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1421-7
|
|
|
|
|
|
15) Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Brit J Haematol. 2000; 111: 1010
|
|
|
|
|
|
16) Totterman TH, et al. Treatment of pure red-cell aplasia and aplastic anaemia with cyclosporine: long-term clinical effects. Eur J Haematol. 1989; 42: 126-33
|
|
|
|
|
|
17) Oshimi K, Yamada O, Kaneko T, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia. 1993; 7: 782-8
|
|
|
|
|
|
18) Clark AD, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood. 1984; 63: 277-86
|
|
|
|
|
|
19) Zaentz SD, Krantz SB, Brown EB. Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs. Brit J Haematol. 1976; 32: 47-54
|
|
|
|
|
|
20) Zecca M, Stefano P, Nobili B, et al. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001; 97: 3995-7
|
|
|
|
|
|
21) Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood. 2002; 99: 1092-4
|
|
|
|
|
|
22) Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003; 123: 278-81
|
|
|
|
|
|
23) Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica. 2005; 90 Suppl: ECR33
|
|
|
|
|
|
24) Mandreoli M, Finelli C, Lopez A, et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis. 2004; 44: 757-61
|
|
|
|
|
|
25) Vichinsky E, Onyekwere O, Porter J, et al. Deferasirox in Sickle Cell Investigators. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007; 136: 501-8
|
|
|
|
|